Todd Gluth

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Cooley advised Gimmal, a developer of information management and enterprise content management software and a portfolio company of Rubicon Technology Partners, on its acquisition by Morae Global, a provider of legal and compliance consulting services

Cooley advised Vision Government Solutions, a portfolio company of Rubicon Technology Partners and a leader in the appraisal, computer-assisted mass appraisal and property tax industry, on its majority recapitalization with Great Hill Partners.

Cooley advised Cerberus Capital Management, a global leader in alternative investing with approximately $65 billion in assets across complementary credit, real estate and private equity strategies, on its growth investment in Aquatech, a global leader in water technology and services for industrial and infrastructure markets.